Navigation Links
Molecular Breast Imaging Outperforms MRI for Patients With Inconclusive Results in the Diagnosis of Cancer
Date:12/3/2008

CHICAGO, Dec. 3 /PRNewswire/ -- Breast-Specific Gamma Imaging (BSGI) has equivalent sensitivity and better specificity than breast MRI in patients with inconclusive findings after mammography and ultrasound in the diagnosis of breast cancer, according to findings presented today at the annual meeting of the Radiological Society of North America (RSNA). BSGI is a molecular breast imaging technique used as an adjunctive tool to mammography that can identify lesions independent of tissue density.

"The purpose of this study was to compare MRI and BSGI in women with indeterminate findings after applying mammography and ultrasound. We found BSGI has virtually equal sensitivity and better specificity than breast MRI in the diagnosis of breast cancer," said Dr. Leora Lanzkowsky.

Dr. Leora Lanzkowsky, as Medical Director of the Eisenhower Medical Center in Rancho Mirage, CA and her colleagues conducted BSGI and breast MRI on patients with complex, inconclusive mammographic and/or ultrasonic findings. In their group of 48 patients with 63 abnormalities, BSGI and MRI yielded consistent results in 37 of these areas and were inconsistent in 26. MRI was inconclusive in a greater number of benign cases -- 10 versus three on BSGI. Overall, in this group of patients with difficult to diagnose breast findings, the sensitivity of BSGI and MRI was 96 percent and 88 percent respectively; specificity was 46 percent and 27 percent respectively.

The advantages of BSGI over MRI include ease of interpretation with fewer images generated, and better tolerance of the test by patients. In addition, BSGI can be used in all patients including those with ferromagnetic implants or renal insufficiency.

BSGI for the study was conducted using a Dilon 6800 Gamma Camera, a high-resolution, small field-of-view gamma camera, optimized to perform BSGI. With BSGI, the patient receives a pharmaceutical tracing agent that is absorbed by all the cells in the body. Due to their increased rate of metabolic activity, cancerous cells in the breast absorb a greater amount of the tracing agent than the normal surrounding tissue and generally appear as "hot spots" on the BSGI image.

"Both tests are good in detecting breast cancer with similar sensitivity for cancer. Along with benefits of cost-effectiveness and comfort, BSGI can be more helpful in excluding inconclusive MRI results. The use of BSGI in this group can result in fewer unnecessary MRI guided biopsies. The reassurance from a truly negative test, indicating that she does not have breast cancer, is priceless information for the patient," said Dr. Lanzkowsky. The work will continue at the Nevada Imaging Centers in Las Vegas, where a new state of the art breast center in association with a high risk clinic will incorporate the Breast specific gamma imaging technology with other state of the art technologies in the assessment of women with both moderate as well as high risk for the development of breast cancer.

About Dilon Technologies

Dilon Technologies Inc. is bringing innovative new medical imaging products to market. Dilon's cornerstone product, the Dilon 6800, is a high-resolution, small field-of-view gamma camera, optimized to perform BSGI, a molecular breast imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake. Many leading medical centers around the country are now offering BSGI to their patients, including: Cornell University Medical Center, New York; George Washington University Medical Center, Washington, D.C.; and The Rose, Houston. For more information on Dilon Technologies please visit http://www.dilon.com.


'/>"/>
SOURCE Dilon Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. A new molecular zip code, and a new drug target for Huntingtons disease
2. New knock-out gene model provides molecular clues to breast cancer
3. Molecular probe paints cancer cells in living animals, Stanford researchers find
4. Story ideas from molecular & cellular proteomics
5. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
6. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
7. Molecular fingerprint of breast-cancer drug resistance can predict response to treatment
8. Molecular profiling can accurately predict survival in colon cancer patients
9. Xceed Molecular Names Fran Tuttle to Its Board of Trustees
10. Virginia G. Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative
11. Xceed Molecular Launches Ziplex(R) Automated Gene-Expression System at the Association for Molecular Pathology, Booth 84/85
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Global Blood Therapeutics, ... company developing novel therapeutics for the treatment of ... announced the closing of its previously announced underwritten ... at the public offering price of $18.75 per ... were offered by GBT. GBT estimates net proceeds ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... and Markets has announced the addition of the ... their offering. ... products and provides an updated review, including its applications ... covering the total market, which includes three main industries: ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
Breaking Medicine Technology: